We have examined whether pharmacologic activation of Nrf2 using the acetylenic tricyclic bis(cyano enone) compound TBE-31 can suppress NASH in mice in which diet-stimulated metabolic disease had already been established, reflecting the situation encountered in clinical practice. Here, NFE2L2 is linked to metabolic dysfunction-associated steatohepatitis.